CEBP  Translational Cancer Medicine 2008: Cancer Clinical Trials and Personalized Medicine
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rebbeck, T. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rebbeck, T. R.
Cancer Epidemiology Biomarkers & Prevention Vol. 11, 945-952, October 2002
© 2002 American Association for Cancer Research


Reviews

Inherited Genotype and Prostate Cancer Outcomes1

Timothy R. Rebbeck2

Department of Biostatistics and Epidemiology, Center for Clinical Epidemiology and Biostatistics, and Cancer Center, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104-6021

Abstract

Prostate cancer is the most commonly diagnosed noncutaneous tumor in North American men and confers significant morbidity and mortality to the general population. The use of screening tools to detect prostate cancer at an early stage may have beneficial effects on an individual’s prognosis. However, the intense use of these screening modalities also detects tumors that may have a relatively benign course and for which intensive treatment is not necessary. There is a large body of research that evaluated biochemical, physiological, or somatic genetic measures in relation to prostate cancer progression or prognosis. Environmental exposures may also affect these outcomes. In contrast, inherited markers of genetic susceptibility to prostate cancer have largely been used to predict occurrence of disease rather than disease outcome. The use of inherited genetic markers to evaluate prostate cancer outcome could enhance our ability to identify those men who are more likely to develop clinically significant prostate cancer and to intervene in these men to reduce morbidity and mortality resulting from prostate cancer.




This article has been cited by other articles:


Home page
JCOHome page
K. Hemminki, J. Ji, A. Forsti, J. Sundquist, and P. Lenner
Concordance of Survival in Family Members With Prostate Cancer
J. Clin. Oncol., April 1, 2008; 26(10): 1705 - 1709.
[Abstract] [Full Text] [PDF]


Home page
Hum Mol GenetHome page
D. J. Schaid
The complex genetic epidemiology of prostate cancer
Hum. Mol. Genet., April 1, 2004; 13(90001): R103 - 121.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
G. Narla, S. L. Friedman, and J. A. Martignetti
Kruppel Cripples Prostate Cancer: KLF6 Progress and Prospects
Am. J. Pathol., April 1, 2003; 162(4): 1047 - 1052.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
Copyright © 2002 by the American Association for Cancer Research.